<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Polo-like kinase 1 (PLK1) is a serine/threonine protein kinase considered to be the master player of cell-cycle regulation during mitosis </plain></SENT>
<SENT sid="1" pm="."><plain>It is indeed involved in centrosome maturation, bipolar spindle formation, chromosome separation, and cytokinesis </plain></SENT>
<SENT sid="2" pm="."><plain>PLK1 is overexpressed in a variety of human <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and its overexpression often correlates with poor prognosis </plain></SENT>
<SENT sid="3" pm="."><plain>Although five different PLKs are described in humans, <z:mpath ids='MPATH_63'>depletion</z:mpath> or inhibition of kinase activity of PLK1 is sufficient to induce cell-cycle arrest and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines and in xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> models </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NMS</z:e>-P937 is a novel, orally available PLK1-specific inhibitor </plain></SENT>
<SENT sid="5" pm="."><plain>The compound shows high potency in proliferation assays having low nanomolar activity on a large number of cell lines, both from solid and hematologic <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NMS</z:e>-P937 potently causes a mitotic cell-cycle arrest followed by <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cell lines and inhibits xenograft <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> with clear PLK1-related mechanism of action at well-tolerated doses in mice after oral administration </plain></SENT>
<SENT sid="7" pm="."><plain>In addition, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NMS</z:e>-P937 shows potential for combination in clinical settings with approved cytotoxic drugs, causing <z:mp ids='MP_0010537'>tumor regression</z:mp> in HT29 human <z:mp ids='MP_0009314'>colon adenocarcinoma</z:mp> xenografts upon combination with irinotecan and prolonged survival of animals in a disseminated model of <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> in combination with <z:chebi fb="0" ids="28680">cytarabine</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NMS</z:e>-P937, with its favorable pharmacologic parameters, good oral bioavailability in rodent and nonrodent species, and proven antitumor activity in different preclinical models using a variety of dosing regimens, potentially provides a high degree of flexibility in dosing schedules and warrants investigation in clinical settings </plain></SENT>
</text></document>